drugset / Trial / NCT01205087
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
RandomizedParallel-groupSingle-blindTreatment
Summary
This clinical study is designed to evaluate the safety and immune modulatory effects of oral administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the metabolic syndrome.
Timeline
- Start
- 2010-09
- Primary completion
- 2010-12
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | muromonab-CD3 | Monoclonal antibody | 0.2 mg | Oral |
| Comparator | muromonab-CD3 | Monoclonal antibody | 1 mg | Oral |
| Comparator | muromonab-CD3 | Monoclonal antibody | 5 mg | Oral |